Several brokerages have updated their recommendations and price targets on shares of Trevi Therapeutics (NASDAQ: TRVI) in the last few weeks:
- 5/9/2026 – Trevi Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 5/8/2026 – Trevi Therapeutics was given a new $30.00 price target by Stifel Nicolaus.
- 5/6/2026 – Trevi Therapeutics had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $20.00 price target on the stock.
- 5/6/2026 – Trevi Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $21.00 price target on the stock.
- 5/6/2026 – Trevi Therapeutics had its price target lowered by Needham & Company LLC from $24.00 to $23.00. They now have a “buy” rating on the stock.
- 4/20/2026 – Trevi Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 4/17/2026 – Trevi Therapeutics had its “buy” rating reaffirmed by D. Boral Capital. They now have a $19.00 price target on the stock.
Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.
Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.
See Also
- Five stocks we like better than Trevi Therapeutics
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Trevi Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
